Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ26489112 in Treatment-Resistant Major Depressive Disorder
NCT01114698Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-26489112 in major depressive disorder (MDD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Mar 2011; status: terminated.
02
Drugs
JNJ-26489112
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01114698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01114698.